The stocks of MRNA will be producing their next quarterly reports on the 6th of May before the market ends up opening. Quite a few analysts have predicted that the company will be announcing its EPS of $2.62 for this quarter. People who seem to be interested in being a part of this conference call can do so from the official website.
The Quarterly Estimates Of MRNA
MRNA did produce their previous quarterly results on the 25th of February. The EPS reported by the company during this quarter was $0.69, which was more than the consensus estimate put forward at $0.25. The net margin for the company has been set at -242.73%, with a -28.11% return on equity. The revenue generated by the company during this period was $570 million, which is comprehensively more than the consensus estimate of $279.41 million. Just the previous year, the EPS reported by the company was $0.37.
The stocks of MRNA traded on Thursday at $178.68. The current ratio of the company is 2.43, with a 2.43 quick ratio, along with a 0.04 debt-to-equity ratio. The year low of the company is $45.01, with a year high of around $129.56. The market cap of the firm is $71.57 billion, with a -110.30 PE ratio, and a 0.53 PEG ratio.
There have been quite a few research equities that have commented on the stocks of MRNA. SVB Leerink has already reaffirmed the rating of the company to sell in an 18th April research report. Jefferies Financial Group has also increased the price target of the company from $150 to $180 in an 18th February research report. Piper Sandler has also reiterated its rating of overweight with a price target of $234 in a 21st April research note.